Gryphon Bio
Private Company
Funding information not available
Overview
Gryphon Bio is a San Francisco-based biotech founded in 2019, pioneering diagnostic-powered therapeutics for brain health. The company's core technology is based on the discovery of thousands of brain-derived molecules in the blood, which fluctuate like waves and provide a novel window into brain conditions. Its initial focus is on developing blood-based biomarker panels for traumatic brain injury (TBI) and Alzheimer's disease (AD), aiming to aid in early detection, monitoring, and therapeutic development. Gryphon is backed by over $13 million in non-dilutive grant funding and is engaging in clinical studies with various partners to validate its tests.
Technology Platform
Proprietary platform based on the discovery of dynamic 'waves' of thousands of brain-derived molecules (e.g., proteins) in peripheral blood, identified through over 20 years of -omic research, used to develop multi-analyte biomarker panels for neurological conditions.
Opportunities
Risk Factors
Competitive Landscape
Gryphon operates in a competitive space with established diagnostic firms (e.g., Quest, LabCorp) and biotechs (e.g., C2N Diagnostics, Quanterix) pursuing blood-based biomarkers for Alzheimer's and TBI. Its differentiation lies in its novel 'wave' biomarker theory, focus on multi-analyte panels for monitoring, and specific targeting of military/veteran health needs.